Literature DB >> 21643003

The development and functions of CD4(+) T cells expressing a transgenic TCR specific for an MHC-I-restricted tumor antigenic epitope.

Xue Han1, Peiying Ye, Liqun Luo, Linghua Zheng, Yang Liu, Lieping Chen, Shengdian Wang.   

Abstract

It has been reported that the ratio of CD4(+) to CD8(+) T cells has no bias in a few class I major histocompatibility complex (MHC-I)-restricted T-cell receptor (TCR)-transgenic mice specific for alloantigens or autoantigens, in which most CD4(+) T cells express an MHC-I-restricted TCR. In this study, we further showed that more than 50% of CD4(+) T cells in MHC-I-restricted P1A tumor antigen-specific TCR (P1ATCR)-transgenic mice could specifically bind to MHC-I/P1A peptide complex. P1A peptide could stimulate the transgenic CD4(+) T cells to proliferate and secrete both type 1 helper T cell and type 2 helper T cell cytokines. The activated CD4(+) T cells also showed cytotoxicity against P1A-expressing tumor cells. The analysis of TCR α-chains showed that these CD4(+) T cells were selected by co-expressing endogenous TCRs. Our results show that CD4(+) T cells from P1ATCR transgenic mice co-expressed an MHC-I-restricted transgenic TCR and another rearranged endogenous TCRs, both of which were functional.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21643003      PMCID: PMC4002444          DOI: 10.1038/cmi.2011.14

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  17 in total

Review 1.  Allelic exclusion of the T cell receptor alpha-chain: developmental regulation of a post-translational event.

Authors:  N R Gascoigne; S M Alam
Journal:  Semin Immunol       Date:  1999-10       Impact factor: 11.130

Review 2.  Regulation of TCR alpha and beta gene allelic exclusion during T-cell development.

Authors:  M Malissen; J Trucy; E Jouvin-Marche; P A Cazenave; R Scollay; B Malissen
Journal:  Immunol Today       Date:  1992-08

3.  Thymocyte-intrinsic genetic factors influence CD8 T cell lineage commitment and affect selection of a tumor-reactive TCR.

Authors:  Anil Shanker; Nathalie Auphan-Anezin; Patrick Chomez; Laurent Giraudo; Benoît Van den Eynde; Anne-Marie Schmitt-Verhulst
Journal:  J Immunol       Date:  2004-04-15       Impact factor: 5.422

4.  Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen.

Authors:  H Pircher; K Bürki; R Lang; H Hengartner; R M Zinkernagel
Journal:  Nature       Date:  1989-11-30       Impact factor: 49.962

5.  Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes.

Authors:  P Kisielow; H Blüthmann; U D Staerz; M Steinmetz; H von Boehmer
Journal:  Nature       Date:  1988-06-23       Impact factor: 49.962

6.  A spontaneous CD8 T cell-dependent autoimmune disease to an antigen expressed under the human keratin 14 promoter.

Authors:  Maureen A McGargill; Dita Mayerova; Heather E Stefanski; Brent Koehn; Evan A Parke; Stephen C Jameson; Angela Panoskaltsis-Mortari; Kristin A Hogquist
Journal:  J Immunol       Date:  2002-08-15       Impact factor: 5.422

7.  Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide.

Authors:  B Lethé; B van den Eynde; A van Pel; G Corradin; T Boon
Journal:  Eur J Immunol       Date:  1992-09       Impact factor: 5.532

8.  T cell receptor genes in a series of class I major histocompatibility complex-restricted cytotoxic T lymphocyte clones specific for a Plasmodium berghei nonapeptide: implications for T cell allelic exclusion and antigen-specific repertoire.

Authors:  J L Casanova; P Romero; C Widmann; P Kourilsky; J L Maryanski
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

9.  Critical role for CD8 in T cell receptor binding and activation by peptide/major histocompatibility complex multimers.

Authors:  M A Daniels; S C Jameson
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

10.  The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice.

Authors:  B Van den Eynde; B Lethé; A Van Pel; E De Plaen; T Boon
Journal:  J Exp Med       Date:  1991-06-01       Impact factor: 14.307

View more
  2 in total

1.  YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment.

Authors:  Xiaochen Yang; Wing Lam; Zaoli Jiang; Fulan Guan; Xue Han; Rong Hu; Wei Cai; William Cheng; Shwu-Huey Liu; Peikwen Cheng; Yuping Cai; Nicholas J W Rattray; Caroline H Johnson; Lieping Chen; Yung-Chi Cheng
Journal:  Sci Rep       Date:  2021-06-29       Impact factor: 4.379

2.  Combined adjuvants of poly(I:C) plus LAG-3-Ig improve antitumor effects of tumor-specific T cells, preventing their exhaustion.

Authors:  Yosuke Kano; Takahiro Iguchi; Hiroto Matsui; Keishi Adachi; Yukimi Sakoda; Tomoya Miyakawa; Shun Doi; Shoichi Hazama; Hiroaki Nagano; Yoshiya Ueyama; Koji Tamada
Journal:  Cancer Sci       Date:  2016-04       Impact factor: 6.716

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.